Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.66 |
| ▸ | JAK3 | P52333 | 2/20 | 0.66 |
| ▸ | PTGES | O14684 | 17/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3624348 | 0.94 | JAK2 (0.63) | JAK2JAK3PTGESCYP2C9CYP2D6 | |
| SCHEMBL3627232 | 0.87 | JAK2 (0.62) | JAK2JAK3PTGESCYP2C9JAK1 | |
| SCHEMBL3621788 | 0.86 | JAK2 (0.74) | JAK2JAK3PTGESCYP2C9CYP2D6 | |
| SCHEMBL3615757 | 0.86 | JAK2 (0.74) | JAK2JAK3PTGESCYP2C9CYP2D6 | |
| SCHEMBL3617219 | 0.85 | JAK2 (0.70) | JAK2JAK3PTGESCYP2C9CYP2D6 | |
| SCHEMBL3613476 | 0.85 | JAK2 (0.65) | JAK2JAK3PTGESCYP2C9CYP2D6 | |
| SCHEMBL3617147 | 0.83 | JAK2 (0.63) | JAK2JAK3PTGESCYP2C9CYP2D6 | |
| SCHEMBL3621069 | 0.83 | JAK2 (0.70) | JAK2JAK3PTGESCYP2C9CYP2D6 | |
| SCHEMBL3619383 | 0.83 | JAK2 (0.73) | JAK2JAK3PTGESCYP2C9CYP2D6 | |
| SCHEMBL3620572 | 0.83 | JAK2 (0.70) | JAK2JAK3PTGESCYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032141-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | claimed |
| EP-2032141-B1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | disclosed |
| US-7763634-B2 | Inhibitors of janus kinases | MERCK & CO., INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090306071-A1 | Inhibitors of Janus Kinases | MERCK SHARP & DOHME LLC | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306071-A1 | Inhibitors of Janus Kinases | JAK2, JAK3, JAK1 | JAK2 1/4885JAK3 2/4885PTGES 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.